CClinicalTrials.gg
Status unknownNCT03619434Updated Dec 22, 2020

Femtolaser Assisted Keratoplasty Versus Conventional Keratoplasty

An interventional study of Femtosecond Laser and Trephine blade in Keratoconus, Fuchs Dystrophy and Corneal Disease, sponsored by University of Southampton. Status unknown at 1 site in United Kingdom. Open to participants aged 16 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-12-22.

Sponsored by University of Southampton · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
16 Years to 90 Years
Sex
All
01

Study summary

This pilot study will compare upto 15 patients undergoing femtolaser assisted keratoplasty (using CE[Conformité Européene] approved femtolaser apparatus) with upto 15 patients undergoing conventional keratoplasty with a manual trephine. Patients will be randomly assigned to either group. All keratoplasties will be penetrating keratoplasties. The following aims of this research is detailed below:

  1. Does femtosecond laser assisted keratoplasty ( FLAK ) yield faster visual recovery and better long term BCVA (Best Corrected Visual Acuity)?
  2. Does FLAK offer a biomechanically stronger cornea and thereby more safety and less risk of wound dehiscence?
  3. Is there any difference between FLAK and conventional keratoplasty in terms of graft failure or rejection?

Follow up in best corrected visual acuity, various refraction/astigmatism measurements, intraocular pressure, graft rejection/failure rates, pachymetry and corneal hysteresis and resistance factor will be recorded at 1 day, 1 week, 1, 3 and 6 months and 1 year and 18 months postoperatively.

This study, to the investigators' knowledge will be the first randomised controlled trial in this area, the first to provide an empirical measurement to biomechanical stability of the cornea with the femtolaser, and the first done in an NHS (National Health Service) setting.

Read the detailed description

Introduction The femtosecond laser has had a profound effect on refractive surgery and, more recently, on cataract surgery and cornea transplantation. The superior precision and control offered by femtosecond laser and its potential use in cornea transplantation show promise in terms of wound stability and strength.

By doing this research project the investigators aim to answer the following questions:

  1. Does femtosecond laser assisted keratoplasty ( FLAK ) yield faster visual recovery and better long term BCVA?
  2. Does FLAK offer a biomechanically stronger cornea and thereby more safety and less risk of wound dehiscence?
  3. Is there any difference between FLAK and conventional keratoplasty in terms of graft failure or rejection?

There have been other studies that have compared femtolaser to the manual trephine in corneal transplant keratoplasty surgery. The investigators' study, to their knowledge, will be the first randomised controlled trial in this area. The majority of interventional studies comparing the two procedures are retrospective case controls. This study, will also be the first to provide an empirical measurement to the biomechanical stability of corneas that have undergone femtolaser corneal transplant. Although theorised to be better with the femtolaser, there has yet to have been a comparative study that has utilised quantitative evidence supporting this. By measuring postoperative corneal hysteresis and corneal resistance factor using an ocular response analyser, the investigators hope to be able to do that.

Recruitment, inclusion/exclusion and method Patients attending the cornea firm at the eye unit in University Hospitals Southampton who are indicated for penetrating keratoplasty as a result of corneal disease or pathology will be recruited. The participants have no connection to the university or the researcher that is known before the research starts. The aim for this study is to have a minimum of 10 patients recruited altogether and a maximum of 30.

Inclusion criteria: • Eyes with corneal opacities owing to previous corneal pathology.

Exclusion criteria: • Eyes with concomitant ocular pathology which may affect visual acuity.

  • Eyes who received previous corneal grafts. Only after the patient has given their informed consent and confirmation that they meet the criteria will they be formally included in the study.

After inclusion in the study participants will be randomised into two groups of equal numbers to either undergo femtolaser-assisted penetrating keratoplasty or to undergo conventional keratoplasty. Other than the use of instrument to make incisions for the graft on the host cornea, all other aspects of the surgery will be kept as homogenous as possible.

Patients will stay overnight or have this operation done as a day case depending on time of day the operation is done. They will then be followed up at 1 day, 1 week, 1 months, 3 months, 6 months, 12 months and 18 months in various different visual outcome measurements as well as biomechanical measures of corneal healing. The two groups will be statistically compared at each timepoint.

This study also has a further role as a pilot study to assess the feasibility of doing a study like this on a larger scale, as a randomised, controlled trial.

Consent Patients who are deemed to not have capacity will not be eligible for this study as they cannot proceed with the consent form. All staff involved in the study have appropriate training in how to judge capacity.

For those with capacity, they will read the patient information sheet first. The patient information sheet contains in layman's terms full details for potential research participants, covering issues from why the researchers are doing the study, what the researchers expect from them, the possibility of adverse effects and anonymity and confidentiality. If patients are still interested after that they will receive a consent form to be signed by them. They will be given a copy of the signed consent form to keep.

Risks, burdens and benefits Risks are explained in the patient information sheet so patients have a fully informed decision about whether to take part in the study. From the investigators point of view it is important to note these patients for this study are indicated for corneal transplant surgery - that is it is felt the benefits of a conventional surgery outweighs the normal risks of corneal transplant surgery. Femtolaser keratoplasty is not known to add any risks that is not present in conventional keratoplasty. It is CE approved for the use in creating cuts in the cornea, as the surgeons are doing for corneal transplants.

Confidentiality The nature of this study means that their details will be known to the surgeons and staff performing the surgery in data collection but these will be coded/anonymised for members of the team involved in other parts of the study, leaving the number of people who know linking details to a minimum. Any documents linking the patient's details to the code will only be the responsibility of the surgeons and their staff. The consent forms themselves will be kept inside a locked storage unit in the Southampton Eye Unit. The patients will be reassured their personal details will not be known to any of the researchers other than the surgeons and their staff that will carry out the surgery.

02

Conditions studied

  • Keratoconus
  • Fuchs Dystrophy
  • Corneal Disease

Keywords

  • Femtolaser
  • Corneal Transplant
  • Keratoplasty
  • Corneal Graft
  • Laser
  • Trephine
03

In context

Keratoconus

307 studies on the registry are indexed under Keratoconus; 56 are open to participants now.

This study's planned enrollment of 30 is below the median of 40 across 203 interventional studies indexed under Keratoconus.

Browse Keratoconus studies →

Lead sponsor

University of Southampton is the lead sponsor of 121 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Eyes with corneal opacities owing to previous corneal pathology.

Exclusion criteria

Exclusion Criteria:

  • Eyes with concomitant ocular pathology which may affect visual acuity.
  • Eyes who received previous corneal grafts.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Conventional keratoplasty group (Control)

    This group will undergo conventional penetrating keratoplasty with a trephine blade.

    Procedure: Trephine blade

  • Experimental
    Femtolaser group

    This group will undergo femtosecond laser-assisted penetrating keratoplasty.

    Procedure: Femtosecond Laser

Interventions

  • ProcedureFemtosecond Laser

    The laser will be used to make incisions in the cornea for the graft.

  • ProcedureTrephine blade

    A trephine blade will be used to make incisions in the cornea for the graft

06

What researchers measure

Primary outcomes

  1. Best Corrected Visual Acuity

    Measure of clarity of vision

    Time frame: Followed up periodically for upto 18 months

  2. Subjective refraction

    A measure of refractive error

    Time frame: Followed up periodically for upto 18 months

  3. Intraocular pressure

    Fluid pressure inside the eye

    Time frame: Followed up periodically for upto 18 months

  4. Corneal hysteresis

    Measure of biomechanical stability of the cornea. Will be done by one machine (Ocular Response Analyser)

    Time frame: Followed up once at 3 months

  5. Corneal topography

    A visual outcome measure assessing corneal curvature. Will be done using a pentacam.

    Time frame: Followed up periodically for upto 18 months

  6. Endothelial cell density

    A measure of healing in the new graft

    Time frame: Followed up periodically for upto 18 months

  7. Corneal Resistance Factor

    Measure of biomechanical stability of the cornea. Will be done by one machine (Ocular Response Analyser)

    Time frame: Followed up once at 3 months

  8. Keratometry

    A visual outcome measure assessing corneal curvature. Will be done using a pentacam.

    Time frame: Followed up periodically for upto 18 months

  9. Pachymetry

    A visual outcome measure assessing corneal thickness. Will be done using a pentacam,

    Time frame: Followed up periodically for upto 18 months

  10. Corneal irregularity index

    A visual outcome measure assessing corneal curvature. Will be done using a pentacam.

    Time frame: Followed up periodically for upto 18 months

  11. Astigmatism

    A visual outcome measure assessing corneal curvature. Will be done using a pentacam.

    Time frame: Followed up periodically for upto 18 months

07

Study locations

1 of 1 sites recruiting
  • Southampton Eye Unit
    Southampton, Hampshire SO16 6YD, United Kingdom
    • Parwez Hossain, MhCHb, PhD · Contact · P.N.Hossain@soton.ac.uk · 02381204270
    • Parwez Hossain, MhCHb, PhD · Principal investigator
    • Joshua Adeyoju, Student · Sub investigator
    • Omar El-Haddad, Corneal Research Fellow · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03619434
Lead sponsor
University of Southampton
Responsible party
Sponsor
First posted
Aug 7, 2018
Start date
Feb 1, 2019
Primary completion
Dec 26, 2021 (estimated)
Completion
Dec 26, 2021 (estimated)
Last update
Dec 22, 2020

Study contacts

Parwez N Hossain, MB ChB, PhD
Contact
P.N.Hossain@soton.ac.uk
02381204270
Parwez Hossain, B ChB, PhD
principal investigator · University of Southampton

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion